Literature DB >> 16736948

HIV transmission and primary drug resistance.

Dan Turner1, Mark A Wainberg.   

Abstract

Transmission of HIV viruses harboring resistance mutations is already a major concern in developed countries, with the potential to impact on therapeutic strategies. Several factors influence the transmission of such viruses, including viral replication fitness and transmission fitness, although behavioral characteristics must also be considered. Rates of transmission of specific mutations are related to therapeutic strategies. Reports of the transmission of multidrug-resistant viruses should alarm the medical community. An additional concern is the use of monotherapy with nevirapine for the prevention of mother-to-child transmission of HIV in developing countries as this practice selects for resistance to nonnucleoside reverse transcription inhibitors and could limit future therapeutic options of both the mothers and infected children. HIV treatment guidelines have evolved, shifting from more aggressive to more conservative approaches. This change of strategy has had a direct impact on the prevalence of drug-resistant virus in the population and the transmission of resistant viral species.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736948

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  18 in total

Review 1.  Novel targets for antiretroviral therapy: clinical progress to date.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Authors:  Annette N Ratcliff; Wuxian Shi; Eric J Arts
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

3.  Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.

Authors:  Peter K Quashie; Thibault Mesplède; Ying-Shan Han; Maureen Oliveira; Diane N Singhroy; Tamio Fujiwara; Mark R Underwood; Mark A Wainberg
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

4.  Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors.

Authors:  Eric Delwart; Elizabeth Slikas; Susan L Stramer; Hany Kamel; Debra Kessler; David Krysztof; Leslie H Tobler; Danielle M Carrick; Whitney Steele; Deborah Todd; David J Wright; Steven H Kleinman; Michael P Busch
Journal:  J Infect Dis       Date:  2012-01-31       Impact factor: 5.226

5.  Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.

Authors:  Hong-Tao Xu; Eugene L Asahchop; Maureen Oliveira; Peter K Quashie; Yudong Quan; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

6.  Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.

Authors:  Thomas A Toni; Eugene L Asahchop; Daniela Moisi; Michel Ntemgwa; Maureen Oliveira; Bernard Masquelier; Bluma G Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

7.  Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Authors:  Clayton D Harro; Michael N Robertson; Michelle A Lally; Lori D O'Neill; Srilatha Edupuganti; Paul A Goepfert; Mark J Mulligan; Frances H Priddy; Sheri A Dubey; Lisa S Kierstead; Xiao Sun; Danilo R Casimiro; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Devan V Mehrotra
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

8.  Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa.

Authors:  Julius M Nwobegahay; Pascal O Bessong; Tracy M Masebe; Lufuno G Mavhandu; Benson C Iweriebor; Gloria Selabe
Journal:  J Health Popul Nutr       Date:  2011-08       Impact factor: 2.000

9.  AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus.

Authors:  Hadija H Semvua; Gibson S Kibiki
Journal:  BMC Res Notes       Date:  2011-11-24

10.  Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.

Authors:  Karin J Metzner; James M Binley; Agegnehu Gettie; Preston Marx; Douglas F Nixon; Ruth I Connor
Journal:  Retrovirology       Date:  2006-12-21       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.